• Health & Medicine

Lower overall dosage of radiotherapy in fewer larger doses as safe for breast cancer patients

The chronic side-effects of radiotherapy for early breast cancer, as reported by women themselves, are not any worse when treatment is given in a lower overall dose in fewer but larger treatments according to a trial part funded by Cancer Research UK and published today in the Lancet Oncology. The chronic side-effects of radiotherapy for early breast cancer, as reported by women themselves, are not any worse when treatment is given in a lower overall dose in fewer but larger treatments according to a trial part funded by Cancer Research UK and published today in the Lancet Oncology.

8 February 2010

• Science & Technology
• Health & Medicine

CRT and AstraZeneca form major alliance to create cancer metabolism drugs

Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday). Cancer Research UKїs commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

7 February 2010

• Health & Medicine

Dundee leads Scotland in launching new cancer research centre

Dundee today (Thursday) becomes Scotland's first link in a unique chain of Cancer Research UK Centres that are being launched across the UK. The launch of the Dundee Centre coincides with World Cancer Day. Dundee today (Thursday) becomes Scotland's first link in a unique chain of Cancer Research UK Centres that are being launched across the UK. The launch of the Dundee Centre coincides with World Cancer Day.

4 February 2010

• Health & Medicine

Surprising discovery could help scientists refine treatment for advanced melanoma

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell. A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

1 February 2010

• Science & Technology
• Health & Medicine

Deal struck for new investigational anti-cancer drug to target leukaemia and lymphoma

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday). CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

4 January 2010

• Health & Medicine

CRT to licence telomere targeting agents to Pharminox for drug development

Cancer Research Technology (CRT) - Cancer Research UK's development and commercial arm - and the cancer drug discovery company Pharminox Ltd (Pharminox) today announced that CRT has granted Pharminox an exclusive worldwide licence over its programme targeting telomeres and telomerase - the enzyme that is responsible for maintaining them. Cancer Research Technology (CRT) - Cancer Research UK's development and commercial arm - and the cancer drug discovery company Pharminox Ltd (Pharminox) today announced that CRT has granted Pharminox an exclusive worldwide licence over its programme targeting telomeres and telomerase - the enzyme that is responsible for maintaining them.

13 October 2009

• Health & Medicine

Cardiff scientists take on leukaemia with drugs personalised to individual patients

Cardiff scientists are treating leukaemia by trialling new drugs tailored to individual patientsї genetic make-up. Cardiff scientists are treating leukaemia by trialling new drugs tailored to individual patientsї genetic make-up.

6 October 2009

• Health & Medicine

Experimental drug may work in many cancers

Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. Scientists have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today.

6 October 2009

• Science & Technology
• Health & Medicine

Cancer Research UK ploughs Ј21 million into new Drug Discovery Programmes

CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to Ј16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow. CANCER RESEARCH UK is set to extend its drug discovery effort by investing up to Ј16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

22 September 2009

• Health & Medicine

Discovery 'significant step' in understanding leukaemia drug resistance

Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation* today (Monday). Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation* today (Monday).

8 June 2009

• Science & Technology
• Health & Medicine

CRT, Newcastle University and KuDOS advance DNA-PK research with a new licence

Cancer Research Technology Limited (CRT) has licensed the rights to its DNA-dependent protein kinase (DNA-PK)* inhibitor programme to collaboration partner KuDOS Pharmaceuticals Ltd (KuDOS) - a wholly owned subsidiary of AstraZeneca. Cancer Research Technology Limited (CRT) has licensed the rights to its DNA-dependent protein kinase (DNA-PK)* inhibitor programme to collaboration partner KuDOS Pharmaceuticals Ltd (KuDOS) - a wholly owned subsidiary of AstraZeneca.

15 May 2009

• Science & Technology
• Health & Medicine

Temozolomide sales reach $1 billion

Sales of Temozolomide*, an anti-cancer drug developed by Cancer Research UK scientists, have reached $1 billion**. Sales of Temozolomide*, an anti-cancer drug developed by Cancer Research UK scientists, have reached $1 billion**.

6 February 2009